Treatment of benign prostatic hyperplasia
AssigneeThreshold Pharmaceuticals, Inc.
InventorGeorge Tidmarsh
Life of this patent
Estimating the term…
Abstract
A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis.
Claims20
A method for prophylaxis or treatment of benign prostatic hypertrophy (BPH) comprising administering an effective amount of lonidamine or a lonidamine analog to a human subject in need of such treatment.
A method for treating BPH comprising (a) diagnosing BPH in a patient, (b) administering lonidamine or a lonidamine analog to the patient and (c) determining whether one or more manifestations of BPH are reduced in said patient.
A method for treating BPH comprising (a) administering lonidamine or a lonidamine analog to a patient diagnosed with BPH and (b) determining whether one or more manifestations of BPH are reduced in said patient.
A unit dose oral pharmaceutical composition for treatment of BPH comprising between 1 mg and 70 mg lonidamine.
A unit dose oral pharmaceutical composition for treatment of BPH comprising 200 and 1000 mg lonidamine.
A unit dose oral pharmaceutical composition that is a sustained-release formulation comprising from about 1 mg to about 2000 mg lonidamine.
Dependencies are inferred from the claim text.